DIVA Laboratories Ltd (4153) - Net Assets
Based on the latest financial reports, DIVA Laboratories Ltd (4153) has net assets worth NT$936.07 Million TWD (≈ $29.49 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.38 Billion ≈ $43.59 Million USD) and total liabilities (NT$447.40 Million ≈ $14.10 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of DIVA Laboratories Ltd to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$936.07 Million |
| % of Total Assets | 67.66% |
| Annual Growth Rate | 3.09% |
| 5-Year Change | 4.33% |
| 10-Year Change | N/A |
| Growth Volatility | 16.76 |
DIVA Laboratories Ltd - Net Assets Trend (2017–2025)
This chart illustrates how DIVA Laboratories Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 4153 company net worth.
Annual Net Assets for DIVA Laboratories Ltd (2017–2025)
The table below shows the annual net assets of DIVA Laboratories Ltd from 2017 to 2025. Also explore 4153 net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.03 Billion ≈ $32.42 Million |
-2.50% |
| 2024-12-31 | NT$1.06 Billion ≈ $33.25 Million |
+2.20% |
| 2023-12-31 | NT$1.03 Billion ≈ $32.54 Million |
+1.64% |
| 2022-12-31 | NT$1.02 Billion ≈ $32.02 Million |
+3.02% |
| 2021-12-31 | NT$986.42 Million ≈ $31.08 Million |
-0.25% |
| 2020-12-31 | NT$988.89 Million ≈ $31.16 Million |
-12.74% |
| 2019-12-31 | NT$1.13 Billion ≈ $35.70 Million |
-4.28% |
| 2018-12-31 | NT$1.18 Billion ≈ $37.30 Million |
+46.76% |
| 2017-12-31 | NT$806.75 Million ≈ $25.42 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to DIVA Laboratories Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 34241800000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$64.17 Million | 6.24% |
| Other Components | NT$964.99 Million | 93.76% |
| Total Equity | NT$1.03 Billion | 100.00% |
DIVA Laboratories Ltd Competitors by Market Cap
The table below lists competitors of DIVA Laboratories Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
WeGrow AG
DU:ZN2
|
$58.41 Million |
|
Budi Starch & Sweetener Tbk
JK:BUDI
|
$58.42 Million |
|
Pinar Su Sanayi ve Ticaret AS
IS:PINSU
|
$58.45 Million |
|
ARRAS MINERALS CORP.
F:9RJ
|
$58.47 Million |
|
Pratama Widya Tbk Pt
JK:PTPW
|
$58.41 Million |
|
MHP HOTEL AG INH O.N.
F:CDZ0
|
$58.39 Million |
|
Plastron Precision Co Ltd
TWO:6185
|
$58.39 Million |
|
Coheris SA
PA:COH
|
$58.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DIVA Laboratories Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,055,502,000 to 1,029,163,000, a change of -26,339,000 (-2.5%).
- Net income of 90,540,000 contributed positively to equity growth.
- Dividend payments of 117,337,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$90.54 Million | +8.8% |
| Dividends Paid | NT$117.34 Million | -11.4% |
| Other Changes | NT$458.00K | +0.04% |
| Total Change | NT$- | -2.50% |
Book Value vs Market Value Analysis
This analysis compares DIVA Laboratories Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.80x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$17.90 | NT$31.60 | x |
| 2018-12-31 | NT$19.70 | NT$31.60 | x |
| 2019-12-31 | NT$15.70 | NT$31.60 | x |
| 2020-12-31 | NT$14.86 | NT$31.60 | x |
| 2021-12-31 | NT$16.78 | NT$31.60 | x |
| 2022-12-31 | NT$17.27 | NT$31.60 | x |
| 2023-12-31 | NT$17.60 | NT$31.60 | x |
| 2024-12-31 | NT$17.99 | NT$31.60 | x |
| 2025-12-31 | NT$17.54 | NT$31.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DIVA Laboratories Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.80%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.42%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.32x
- Recent ROE (8.80%) is above the historical average (1.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -33.11% | -31.17% | 0.81x | 1.32x | NT$-347.82 Million |
| 2018 | 4.41% | 8.02% | 0.49x | 1.12x | NT$-66.24 Million |
| 2019 | 4.95% | 7.83% | 0.55x | 1.15x | NT$-57.28 Million |
| 2020 | 1.76% | 2.36% | 0.66x | 1.13x | NT$-81.47 Million |
| 2021 | 2.22% | 3.07% | 0.60x | 1.20x | NT$-76.79 Million |
| 2022 | 4.89% | 5.23% | 0.76x | 1.23x | NT$-51.96 Million |
| 2023 | 7.13% | 8.24% | 0.72x | 1.20x | NT$-29.66 Million |
| 2024 | 8.87% | 10.86% | 0.66x | 1.24x | NT$-11.89 Million |
| 2025 | 8.80% | 10.42% | 0.64x | 1.32x | NT$-12.38 Million |
Industry Comparison
This section compares DIVA Laboratories Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,371,616,000
- Average return on equity (ROE) among peers: -0.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| DIVA Laboratories Ltd (4153) | NT$936.07 Million | -33.11% | 0.48x | $58.41 Million |
| Bionet (1784) | $1.37 Billion | -0.46% | 0.33x | $100.34 Million |
About DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the research, development, manufacture, and sale of medical devices and computer peripherals worldwide. The company provides endo/surgical displays for hybrid and other types of OR applications; color and mono displays for radiology applications; and touch and embedded display, as well as industrial displays. DIVA Laboratories, Ltd. was founded in 1984 and is he… Read more